Abstract Details

Title Impaired Generalization of Acquired Memory Pairings in Preclinical Familial Alzheimer's Disease (FAD) Mutation Carriers

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 139

Objective

Background BACKGROUND: Generalization of arbitrary memory pairings is impaired in persons with medial temporal lobe damage. We hypothesized that this skill would be impaired early in the course of FAD due to fully-penetrant mutations.

Design/Methods DESIGN/METHODS: 31 persons at-risk for inheriting FAD mutations underwent comprehensive evaluations including a lap-top based acquired equivalence task. During a training phase, subjects were implicitly trained on pairings between types of persons (e.g. male vs. female, child vs. adult) and fish of a specific color. Subjects learned the ways in which persons were associated with fish (e.g. females with blue fish, males with green fish) and were then trained on an examplar of a new pairing (a female child with a red fish as opposed to a purple fish). This was followed by a testing phase in which subjects were shown novel combinations (e.g. a female adult and red and purple fish) and were asked to choose the correct pairing (e.g. adult female and red fish). The number of errors was recorded and compared between mutation carriers (MCs) and non-carriers (NCs) using mixed ANOVAs.

Results RESULTS: 22 subjects were FAD MCs and 9 were NCs. They did not differ with regard to age, gender, or MMSE score (mean score of MCs 29.2, range 25-30). 9 MCs had CDR scores of 0.5, suggesting mild impairment, and the rest were asymptomatic. MCs made significantly more errors on generalization trials during the testing phase than NCs (F(1,29) = 9.3, p = 0.005) though the interaction between group and type of trial was only marginally significant (F(1,29)= 2.9, p = 0.099).

Conclusions CONCLUSIONS: Generalization of arbitrary memory pairings tested using this acquired equivalence paradigm is impaired in medial temporal lobe damage, including in preclinical FAD mutation carriers.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Luis D. Medina, PhD (University of Houston)	The institution of Dr. Medina has received research support from National Institutes of Health. Dr. Medina has received personal compensation in the range of $500-$4,999 for serving as a Speaker with AbbVie. Dr. Medina has a non-compensated relationship as a Council Member with Alzheimer's Association that is relevant to AAN interests or activities.
	No disclosure on file
Giovanni Coppola, MD (UCLA)	Dr. Coppola has received personal compensation for serving as an employee of Regeneron. Dr. Coppola has received stock or an ownership interest from Regeneron.
	No disclosure on file
John M. Ringman, MD, FAAN (Keck School of Medicine of USC, Neurology Dept)	The institution of Dr. Ringman has received research support from Avid Pharmaceuticals. The institution of Dr. Ringman has received research support from AltaMed. The institution of Dr. Ringman has received research support from CurePSP.
Benjamin M. Greenberg, MD, FAAN (UT Southwestern Medical Center)	Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has or had stock in GenrAb.Dr. Greenberg has or had stock in Clene.Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��